A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer-Reference-Cited by-同舟云学术

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer

Published:2019-01-09 Issue:4 Volume:24 Page:430-432
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Antonarakis Emmanuel S.¹

Affiliation:

1. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA

Abstract

Immune checkpoint agents have not yet been approved for use in advanced prostate cancer. This commentary summarizes the challenges related to this issue, in light of a recently reported case of a patient with DNA mismatch-repair deficient castration-resistant prostate cancer who responded to single-agent pembrolizumab treatment.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2018-0819

Reference27 articles.

1. Targeting immune checkpoints in cancer therapy;Topalian;JAMA,2017

2. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer;Isaacsson Velho;Expert Rev Clin Pharmacol,2018

3. Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study;Hansen;Ann Oncol,2018

4. Pembrolizumab plus enzalutamide in metastatic castration resistant prostate cancer: Extended follow up;Graff;J Clin Oncol,2018

5. KEYNOTE-199: Pembrolizumab for docetaxel-refractory metastatic castration-resistant prostate cancer;de Bono;J Clin Oncol,2018

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations;Expert Opinion on Biological Therapy;2024-01-31

2. Tertiary Lymphoid Structures Validated as Biomarker;Cancer Discovery;2023-11-22

3. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer;Cancer Discovery;2023-10-20

4. Targeting the spectrum of immune checkpoints in prostate cancer;Expert Review of Clinical Pharmacology;2021-07-15

5. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?;Prostate Cancer and Prostatic Diseases;2021-05-25